GlassScriptPhysician profile
Morgan A Bunch
NPI 1669117834
$1,251.08
in general payments reported to CMS, 2019-2025
22 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $243 · 2023: $488 · 2024: $317 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $436.01 | 2022-2025 | |
| Amgen INC. | $128.65 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.81 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $66.31 | 2022-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $52.02 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $51.92 | 2022 | |
| Baxter Healthcare | $50.34 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Monarch Airway Clearance System |
| Janssen Pharmaceuticals, INC | $41.08 | 2022-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $35.87 | 2023 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $34.44 | 2025 | |
| Boston Scientific Corporation | $33.40 | 2023 | Watchman Access System |
| United Therapeutics Corporation | $26.09 | 2023 | Tyvaso |
| Gilead Sciences, INC. | $24.09 | 2023 | |
| Chiesi USA, INC. | $23.90 | 2023 | Cleviprex, Kengreal |
| Inogen, INC. | $22.01 | 2023 | Inogen At Home Stationary Concentrator |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.95 | 2022 | |
| Verona Pharma, INC. | $19.62 | 2025 | Ohtuvayre |
| Abiomed | $17.82 | 2025 | |
| Lilly USA, LLC | $16.84 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $14.48 | 2025 | Inspire |
| Harmony Biosciences LLC | $14.21 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $13.22 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.